Random Walk

Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership

Perception of valvulopathy risk will always be there. The efficacy of the drug is not that impressive. Many alternatives to lorcaserin exist now, and many more will exist in the future. Tough time with third-party payers. Also, still in Phase III studies. Given all these things, there are probably more compelling biotech investments out there.